AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER – Trademark Portfolio
Entity Type: 03
AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER holds 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include ECOMER, CITANEST, and XYLOCAINE.
Showing of trademarks Trademarks
Trademark Classifications
AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER have?
AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER has 21 U.S. trademarks filed with the USPTO. Of these, 3 registered, 18 cancelled.
What trademark classes does AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER file in?
AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER's most well-known trademarks?
AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER's registered trademark portfolio includes well-known marks such as ECOMER, CITANEST, and XYLOCAINE. These are among 3 currently registered trademarks in the portfolio.
What is AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER's trademark registration success rate?
AKTIEBOLAGET ASTRA, APOTEKARNES KEMISKA FABRIKER has a 14% trademark registration rate, with 3 out of 21 resolved applications resulting in successful registration. Currently, 0 applications are pending review.